| Literature DB >> 29588874 |
Elzinandes Leal Azeredo1, Flavia Barreto Dos Santos1, Luciana Santos Barbosa2, Thiara Manuele Alves Souza1, Jessica Badolato-Corrêa1, Juan Camilo Sánchez-Arcila3, Priscila Conrado Guerra Nunes1, Luzia Maria de-Oliveira-Pinto4, Ana Maria de Filippis5, Márcia Dal Fabbro6, Izilyanne Hoscher Romanholi7, Rivaldo Venancio da Cunha6.
Abstract
BACKGROUND: The current triple epidemic caused by dengue, zika and chikungunya constitutes a serious health problem in Brazil. The aim of this study was to investigate acute samples (up to the 7 days of symptoms) from patients presenting acute fever syndrome suspected as arboviral infection and characterize the clinical and laboratorial profile during the co-circulation of dengue, zika and chikungunya in Campo Grande, Mato Grosso do Sul (MS), midwest region of Brazil.Entities:
Year: 2018 PMID: 29588874 PMCID: PMC5843488 DOI: 10.1371/currents.outbreaks.0bf6aeb4d30824de63c4d5d745b217f5
Source DB: PubMed Journal: PLoS Curr ISSN: 2157-3999
Demographic characteristics of the population and laboratorial parameters of studied patients during the triple epidemic in Campo Grande, MS, Brazil, 2016.
| ZIKVδ | DENV | CHIKV | NEGATIVEϕ | |
|---|---|---|---|---|
| (n = 38) | n = 69) | (n = 7) | (n = 28) | |
| Age | 31 (30.5-40.1) | 32 (32.7-40.3) | 26 (17.5-53.8) | 38 (32.1-44.3) |
| Gender | ||||
| Female: Male (n) | 21:17 | 32:37 | 2:5 | 22:6 |
| Pregnant (n) | 5 | 5 | 0 | 1 |
| Post-infection daysa | 3.5 (3-4.1) | 4.0 (4.1- 6.2) | 3.0 (1.9 – 4.9) | 3.0 (1.3- 5.7) |
| Hospitalization, n (%) | 2 (0.9) | 7 (5.22) | 1 (0.9) | 0 |
| Comorbities | ||||
| Arterial hypertension, n (%) | 8 (7.5) | 12 (11.5) | 2 (1.8) | 1 (0.94) |
| Diabetes mellitus, n (%) | 0 | 2 (1.8) | 2 (1.8) | 0 |
| Other comorbidities♯, n (%) | 9 (8.4) | 19 (17.9) | 1 (0.9) | 8 (7.5) |
Laboratorial diagnosis of arboviruses suspected cases (n=134) analyzed from the triple outbreak occurred in 2016 in Campo Grande, MS, Brazil.
| Laboratorial diagnostic methods | Positive/Tested (%) |
|---|---|
| Dengue IgM ELISA | 30 (22.3) |
| Dengue NS1 ELISA | 50 (37.3) |
| CHIKV IgM ELISA | 7 (5.6) |
| DENV RT-PCR £ | 69 (51.4) |
| DENV-1 | 62 (89.8) |
| DENV-4 | 7 (10.1) |
| ZIKV RT-PCR £ | 38 (28.3) |
| CHIKV RT-PCR | 0 |
| Mono and co-infections | |
| DENV monoinfection¥ | 51 (38.0) |
| ZIKV monoinfectionω | 18 (13.4) |
| DENV/ZIKV coinfection $ω | 18 (13.4) |
Signs and symptoms of zika and dengue infected patients during the 2016 epidemic, in Campo Grande, MS. Brazil.
| Signs and symptoms (%) | ZIKV (n=15) | DENVΦ (n=54) | DENV/ZIKV (n=15) | Negative* (n=28) |
|---|---|---|---|---|
| Fever | 13 (86.6) | 46 (85.1) | 11 (73.3) | 19 (67.8) |
| Headache | 13 (86.6) | 48 (88.8) | †10 (66.6) | 18 (78.5) |
| Conjuctival hyperemia | 8 (53.3) | 19 (43.1) | 9 (60.0) | 7 (25.0) |
| Retro-orbital pain | 14 (93.3) | 43 (79.6) | 11 (73.3) | 15 (60.7) |
| Myalgia | 12 (80.0) | 49 (90.7) | 14 (93.3) | 21 (71.4) |
| Arthralgia | 10 (66.6) | 46 (85.1) | 13 (86.6) | 21 (75.0) |
| Anorexia | 6 (40.0) | 34 (62.9) | 6 (40.0) | 14 (50.0) |
| Prostration | 10 (66.6) | £49 (90.7) | 13 (86.6) | 21 (75.0) |
| Dizziness | 6 (40.0) | 31 (57.4) | 8 (53.3) | 11 (39.2) |
| Nausea | 5 (33.3) | 36 (66.6) | 6 (40.0) | 11 (39.2) |
| Vomiting | 0 | +17 (31.4) | 2 (13.3) | 4 (14.2) |
| Epigastralgia | 0 | 1 (2.1) | 0 | 0 |
| Abdominal pain | 3 (20.0) | 24 (44.4) | 4 (26.6) | 9 (32.1) |
| Adenomegaly | 0 | 1 (1.85) | 0 | 0 |
| Pruritus | £ 13 (86.6) | 28 (51.8) | 7 (46.6) | 21 (75.0) |
| Paresthesia | 6 (40.0) | 17 (31.4) | 5 (33.3) | 8 (28.5) |
| Exanthema | 12 (80.0) | 32 (59.2) | 8 (53.3) | 19 (67.8) |
| Edema | £6 (40.0) | 6 (11.1) | 5 (33.3) | 9 (32.1) |
| Diarrhea | 3 (20.0) | 15 (27.7) | 2 (13.3) | 5 (17.8) |
| Cough | 2 (13.3) | 16 (29.6) | 2 (13.3) | 8 (28.5) |
| Low back pain | 10 (66.6) | 38 (70.3) | 9 (60.0) | 15 (64.2) |
| Painful hepatomegaly | 0 | 2 (3.7) | 2 (13.3) | 1 (3.57) |
Demographic, clinical and laboratorial characteristics of pregnant women enrolled in this study.
| Case | Gestacional age (weeks) | Signs and Symptoms | ZIKV molecular diagnosis | DENV molcular diagnosis | anti-DENV IgM | anti-DENV IgG | DENV NS1 anigen capture | Newborn outcome |
|---|---|---|---|---|---|---|---|---|
| 1 | 27 | Headache, Exanthema, Pruritus, Abdominal pain | + | - | - | + | - | Alive. Healthy child since birth |
| 2 | 20 | Arthralgia, Exanthema, Pruritus | + | - | + | + | + | Alive. Healthy child since birth |
| 3 | 12 | Headache, Prostration, Myalgia, Low back pain, Anorexia, Nausea, Vomiting | - | + | - | + | - | Alive. Healthy child since birth |
| 4 | 9 | Fever, Headache, Prostration, Abdominal pain, Exanthema, Pruritus, Retro-orbital pain | + | + | - | + | - | Alive. Functional plagiocephaly |
| 5 | 28 | Headache, Arthralgia, Low back pain, Exanthema, Pruritus | - | - | - | + | - | Not available |
| 6 | 26 | Fever, Prostration, Myalgia, Arthralgia, Retro-orbital pain, Anorexia, Exanthema, Pruritus | - | + | + | + | + | Alive. Healthy child since birth |
| 7 | 36 | Fever, Headache, Prostration, Low back pain, Retro-orbital pain, Nausea, Exanthema, Pruritus, Dizziness | - | + | - | + | - | Alive. Healthy child since birth |
| 8 | 28 | Fever, Headache, Prostration, Myalgia, Retro-orbital pain | - | + | - | + | - | Not available |
| 9 | 16 | Headache, Myalgia, Arthralgia, Low back pain Exanthema, Pruritus, Retro-orbital pain, Anorexia | + | - | - | + | + | Not available |
| 10 | 20 | Fever, Exanthema, Conjutival hyperemia, Retro-orbital pain | + | + | - | + | - | Deceased. Respiratory insufficiency |
| 11 | 21 | Headache Myalgia | - | - | + | + | + | Alive. Healthy child since birth |
Laboratorial characteristics of the DENV, ZIKV or DENV/ZIKV co-infected patients during the 2016 outbreak occurred in Campo Grande, MS, Brazil.
| Laboratorial parameters | Negative | DENV | ZIKV | DENV/ZIKV |
|---|---|---|---|---|
| AST, IU/L a(95% C.I.) a | 20 (16.9-26.9)(n=11) | 36.4 (36.4-75.8) ++(n=28) | 27.5 (21.4-32.5)(n=8) | 23 (10-115.7)+ (n=9) |
| ALT, IU/L a | 18 (14.1-24.4)(n=9 ) | 33.5 (34.9-59.6) ++ £(n=44) | 23 (17.6-28.0) (n=13) | 24 (11.7-74.7) (n=15) |
| Total proteins (g/dL) | 7.2 (6.9-7.4)(n=18 ) | 7.3 (7.1-7.4)£ (n=46 ) | 7.7 (7.3-7.9)+ (n=13 ) | 7.4 (7.1-7.6) (n=15 ) |
| Total albumin (g/dL) | 4.2 (4.0-4.3)(n=18 ) | 4.0 (4.0-4.3) (n=46 ) | 4.2 (4.0-4.4) (n=13 ) | 4.3 (4.1-4.4) (n=15 ) |
| Hematocrit (%) | 39 (38.7-41.2)(n=23 ) | 41 (39.8-42.1) (n=54) | 41 (39.4-44) (n=15 ) | 43 (39.2-44.2) (n=15 ) |
| Platelets, 103/mm3 counts a | 222.5 (205.5-244)(n=22) | 190 (154.8-194.6)++, (n=54) | 197 (155.5-265.3)(n=15) | 193 (160.1-229.9)(n=15) |
| Leukocytes, mm3 counts | 6200 (5317-7966)(n=17) | 4400 (4599-6860)+(n=53) | 4400 (4102-5178)++ (n=15) | 4600 (3717-7096)(n=15) |
| Lymphocytes, mm3 counts | 2035 (1650-2442)(n=13) | 1558 (1351-1897)(n=50) | 1330 (990.2-2453) +(n=15) | 1136 (1012-1887)+ (n=15) |
| Monocytes, mm3 counts % | 520.5 (415.2-613.1)(n=14) | 396 (362-514.5)(n=50) | 429 (361.1-536.4)(n=15) | 470 (394.1-574.1)(n=15) |
| Neutrophils, mm3 counts % a | 2940 (2573-4225)(n=21) | 2631 (2404-4106)(n=42) | 2187 (1904-3218)(n=12) | 2478 (1832-4928)(n=15) |
| Eosinophils, mm3 counts % a | 124 (104-208)(n=21) | 50.5 (63-148)+(n=42) | 54 (36.5-111)++(n=12) | 44 (23.3-182.3)+(n=15) |
| Basophils, mm3 counts % a | 0.0 (5.3-28)(n=21) | 0.0 (11-46) (n=41) | 19.5 (6.4-52.0)(n=12) | 0.0 (1.9-35.8) (n=15) |
Demographic and laboratory characteristics of suspected cases according to the type of infection (mono or co-infection) during the triple epidemic occurred in Campo Grande, MS, Brazil during 2016.
| DENV | DENV/ZIKV | ZIKV | |||
|---|---|---|---|---|---|
| Demographic and laboratory characteristics | Without WS (n=46) | With WS/Severe (n=8) | Without WS (n=12) | With WS/Severe (n=3) | (n=15) |
| Gender F:M | 22:24 | 6:2 | 5:7 | 1:2 | 12:3 |
| Age Median (LCL-UCL) | 33 (31.1-39.8) | 46.5 (31.15-39.8) | 25.5 (23.4-44.1) | 21 (12-71) | 40 (32.6-45.26) |
| a Days of disease ΩMedian (LCL-UCL) | 3.5 (2.5-4.4) | 4.5 (0.7-11) | 25.5 (23.4-44.1) | 21 (12-71) | 40 (32.6-45.26) |
| DENV-1 (n/total) | 33/38 | 5/6 | 12/13 | 3/3 | 0 |
| DENV-4 (n/total) | 4/38 | 1/6 | 1/13 | 0/3 | 0 |
| Hospitalization (%) | 0 | 1/6 | 0 | 0/3 | 0 |
| AST (IU/L)(n=total) | 33 (36.6-78) (n=24) | 43 (18.9-69)(n=4) | 23 (24-147) (n=7) | 22.5 (16-28)(n=2) | 27.5 (21.4-32.5) (n=8) |
| ALT (IU/L)(n=total) | 39.7 (37-46.4)(n=41) | 62.5 (113-346)(n=4) | 28 (5.8-93) (n=11) | 16 (10-22.5)(n=3) | 23 (17-28.1)(n=13) |
| Total proteins (g/dL) | 7.3 (7.1-7.4)(n=40) | 7.0 (6.4-7.7)(n=6) | 7.3 (7.1-7.4)(n=14) | 7.0 (6.4-7.7)(n=3) | 7.0 (6.4-7.7)(n=15) |
| Albumin (g/dL) | 4.05 (4.07-4.2(n=40) | 4.2 (3.4-4.5)(n=6) | 4.3 (4.1-4.4)(n=14) | 4.1 (2.4-6.0)(n=3) | 4.2 (4.05-4.4)(n=13) |
| Hematocrit (%) | 41 (40.7-42.5)(n=46) | 39.5 (33.9-43)(n=8) | 43 (39-44.6)(n=14) | 39 (26-53.8)(n=3) | 41 (39.4-44.1)(n=15) |
| Platelets 103 /mm3 counts | 198.5 (168-206.6) (n=46) | 101 (39.4-172.1) b***(n=8) | 188 (147-224) | 193 (40-392)(n=3) | 197 (155.5-265.3) |
| Bleeding (%) | 0 | 6 (75%)d | 1 (7.14%)b | 2 (66%) | 0 |